AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01021241 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Uricase-PEG 20
Description: Intravenous infusion of Uricase-PEG 20 over one hour; no premedication
Study NCT03056976 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Two-implant mandibular overdenture
Description: Complete mandibular denture retained by two implants in the canine region
Study NCT03056976 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fixed mandibular denture
Description: A fixed mandibular denture retained by four implants
Study NCT03488121 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Poster
Description: Posters contain inspirational messages and pictures highlighting the important and unique roles that patients and physicians can play in reducing unnecessary care and health care costs. These posters will be placed in physician offices.
Study NCT03627741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide
Description: A concentration of 40 mg/ml of Triamcinolone Acetonide will be used for injections with a total dose of 120 mg of Triamcinolone given per injection. The injections will be performed under ultrasound guidance by a fellowship-trained musculoskeletal radiologist. The injection locations will be left to the discretion of the radiologist with the request to attempt to distribute the drug throughout the tumor. A total of three injections will be performed at six week intervals.
Study NCT04147988 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: screening and diagnostic assessment DONALD T unit list
Description: Screening and diagnostic assessment of the group of people awaiting assessment, and thus test the feasibility of a screening and diagnosis procedure for autism in adults without intellectual disabilities
Study NCT04399876 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Microdevice
Description: Surgery Cohort: Placement of 1-6 microdevices: Drugs chosen have all been FDA approved for the treatment of cancer (so therefore safe) and there are phase 2 or 3 data that the drug has efficacy in prostate cancer. Agents of interest included Abiraterone, Enzalutamide, Pembrolizumab, Ipilimumab, Carboplatin, Docetaxel, and Olaparib as well as combinations~Ex vivo Cohort: Placement of multiple microdevices with miniature drug reservoirs but no drug is loaded into the removed prostate
Study NCT03488121 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Thank-you Letter
Description: Physicians will be sent thank-you letters containing changes in the rates of antibiotics and serum ferritin tests ordered since introduction of Choosing Wisely NL and a thank-you message from the NL Medical Association.
Study NCT00330863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone microspheres
Description: Minimum dose is 12.5 mg every 2 weeks. Maximum dose is 75 mg every 2 weeks.
Study NCT00330863 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: Target dose is 4 mg/day.
Study NCT00330863 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: Target dose is 15 mg/day.
Study NCT00330863 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine
Description: Target dose is 600 mg/day.
Study NCT01473121 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: All treatment options (inc. surgery, TACE, drugs) will be registered.
Study NCT00330863 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ziprasidone
Description: Target dose is 120 mg/day.
Study NCT00330863 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Target dose is 20 mg/day.
Study NCT00330863 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paliperidone
Description: Target dose is 6 mg/day.
Study NCT00999219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FK199B
Description: oral
Study NCT00999219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem
Description: oral
Study NCT00635830 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
Description: HPV 6,11,16,18 VLP, 0.5 mL 1 dose injection.
Study NCT02692729 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transverse supraumbilical
Description: transverse Supraumbilical Incision, in which the skin incision is a straight transverse skin incision slightly higher than the Pfannenstiel (5- 6) cm. from the upper border of the symphysis pubis The high transverse incision facilitated access to the fascia of the rectus abdominalis
Study NCT02692729 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pfannenstiel incision
Description: Pfannenstiel Incision, in which the skin incision is a transverse upward concavity, typically initiated two finger-breadths above the symphysis pubis and extended in the direction of the anterior superior iliac spine below and medial to it about (2 - 3 ) cm.
Study NCT01106521 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Permanent breast seeds implant
Description: Patients are pre-planned using CT simulation. Implant is realised under light sedation and local freezing. Stranded seeds are inserted using a brachytherapy template that is immobilised to the planned target volume using a 'localization' needle. Patients is released the same day and Quality Assurance involves a 2 months post-implant CT
Study NCT01425476 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Take one tablet from each bottle (one bottle containing either placebo/celecoxib and one bottle containing either cholecalciferol 400 IU or 2,000 IU) daily for 30 days.
Study NCT01425476 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Take one tablet from each bottle (one bottle containing either placebo/celecoxib and one bottle containing either cholecalciferol 400 IU or 2,000 IU) daily for 30 days.
Study NCT01425476 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: Take one tablet from each bottle (one bottle containing either placebo/celecoxib and one bottle containing either cholecalciferol 400 IU or 2,000 IU) daily for 30 days.
Study NCT01362218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cardiovascular fixed dose combination pill (acetylsalicylic acid, simvastatin and ramipril)
Description: A once daily oral dose of the cardiovascular fixed dose combination pill ( acetylsalicylic acid, simvastatin, ramipril) for 8 weeks.
Study NCT01362218 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin, ramipril, acetylsalicylic acid
Description: A once daily oral dose of simvastatin, ramipril, acetylsalicylic acid for 8 weeks
Study NCT03196193 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open Reduction and Internal Fixation
Description: Fractured bone fragments are reduced and stabilized by intramedullary nail.
Study NCT03196193 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Reduction and Internal Fixation
Description: Fractured bone fragments are reduced and stabilized by intramedullary nail.
Study NCT03196193 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ZNN CM Asia
Description: Reduced bone fragments are to be stabilized by Zimmer Natural Nail CM Asia System.
Study NCT03196193 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ZNN CM Asia
Description: Reduced bone fragments are to be stabilized by Zimmer Natural Nail CM Asia System.
Study NCT03196193 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anterior Support Screw
Description: Experimental group will receive insertion of ACE 4.5/5.0mm cannulated lag-screw anteriorly to Zimmer Natural Nail CM Asia Lag-screw.
Study NCT04959253 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Psilocybin assisted therapy
Description: A package of psychological therapy and a single dosing session of psilocybin.
Study NCT04959253 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo assisted therapy
Description: A package of psychological therapy and a single dosing session of placebo.
Study NCT05353101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine 0.05% eye drops
Description: Use of 0.05% CSA could significantly reduce IL-4, IL-5, IL-17A, and TNF in tears of VKC patients- α、 IFN- γ And eosinophil chemokine levels. Cyclosporine A (CSA) can effectively control ocular inflammation by blocking Th2 lymphocyte proliferation and IL-2 production. It can also inhibit the recruitment of eosinophils by inhibiting the release of histamine by mast cells and reducing the production of IL-5 further to improve its curative effect on VKC
Study NCT05353101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loteprednol Etabonate 0.5% and Tobramycin Eye Drops 0.3%
Description: Corticosteroids can inhibit the release of mast cells, block the chemotaxis of inflammatory cells, and reduce the number of mast cells and eosinophils in the conjunctiva. At the same time, it can inhibit phospholipase A2 and quickly alleviate symptoms and signs.
Study NCT05014048 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: 20 mikrog vitamin D3 daily
Study NCT01665092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levo-Carnitine
Study NCT01425476 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cholecalciferol
Description: Take one tablet from each bottle (one bottle containing either placebo/celecoxib and one bottle containing either cholecalciferol 400 IU or 2,000 IU) daily for 30 days.
Study NCT01425476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: Take one tablet from each bottle (one bottle containing either placebo/celecoxib and one bottle containing either cholecalciferol 400 IU or 2,000 IU) daily for 30 days.
Study NCT01665092 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT00653276 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ezetimibe
Description: ezetimibe 20 mg (2 x 10 mg tablets) on Days 1 through Day 7.
Study NCT00653276 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: cyclosporine
Description: single oral dose of cyclosporine 100 mg capsules on Day 1 or Day 7.
Study NCT02390544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan is a bifunctional alkylating agent that inhibits DNA and RNA synthesis, cross-links strands of DNA and acts on both resting and rapidly dividing cells including tumor cells. It is administered intravenously.
Study NCT04152421 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Software use
Description: The patient will connect to a computerized platform to access the program. The program consists of 5 modules (lessons), each lasting approximately 40 minutes. Each module or lesson includes pedagogical assessments and explanations of the problem(s) in question, illustrations, testimonies, tips, exercises and recommended activities.
Study NCT03147391 — intervention group
Intervention type: DEVICE
Intervention: LAA closure with LAmbre
Description: Percutaneous Left Atrial Appendage Closure Using the LAmbre Device in Patients With Atrial Fibrillation
Study NCT01537419 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attachment-Based Family Therapy
Description: Although ABFT therapists implement behavior focused and psychoeducational interventions, the model is primarily a process oriented, emotion focused treatment guided by a semi-structured treatment protocol. ABFT aims to improve the family's capacity for problem solving, affect regulation, and organization. This strengthens family cohesion which can buffer against depression, suicidal thinking, and risk behaviors.
Study NCT01537419 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family-Enhanced Non-directive Supportive Therapy
Description: Family-Enhanced Non-directive Supportive Therapy (FE-NST) is a 16 week therapy designed to control for the non-specific effects of psychotherapy with suicidal youth. FE-NST aims toward relief or reduction of symptoms without expectation of change in the basic personality structure. We have added a parent component to: a) control for parent involvement and b) improve the generalizability and safety of the FE-NST treatment. This enhancement consists of 5 potential parent sessions beginning with a family safety plan in the initial treatment session that will be monitored regularly throughout the treatment. The remaining 4 parent psycho-education sessions offer parents knowledge, skills and support to improve management of the suicidal teen.
Study NCT02700958 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning
Description: Remote ischemic preconditioning is performed with standard blood pressure cuff on upper-arm. RIPC will be started just before the coronarography or angiography. Time between the last inflation cycle and the beginning of the procedure will be less than 60 minutes.
Study NCT02700958 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: SHAM Remote ischemic preconditioning
Description: SHAM Remote ischemic preconditioning is performed with standard blood pressure cuff on upper-arm. RIPC-SHAM will be started just before the coronarography or angiography. Time between the last inflation cycle and the beginning of the procedure will be less than 60 minutes
Study NCT05014048 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03831802 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Embrace with Alert and Mate apps
Description: Patients will wear the device on their wrist as often as possible during the day and night. The Embrace Watch contains sensors and memory recordings of electrodermal activity, temperature and physical activity from the wearer. This group will receive notifications on the mobile phone when seizure takes place. Quality of life questionnaires will be filled by the patients at the first follow-up and final assessments.
Study NCT03831802 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Embrace with Mate app only
Description: Patients will wear the device on their wrist as often as possible during the day and night. This group will just use the Mate app that summarizes Embrace Watch data for the owner and captures contextual information around events.This group will not receive any alert notification on the mobile phone when a seizure takes place.
Study NCT04496362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: subcutaneous heparin anticoagulation
Description: The primary objective of this study is to evaluate the safety and efficacy of subcutaneous heparin anticoagulation compared to the standard of care systemic intravenous anticoagulation during veno-venous extracorporeal membrane oxygenation for respiratory failure. Subjects will be prospectively randomized in 1:1 ratio to subcutaneous heparin anticoagulation or systemic intravenous anticoagulation and followed until 1 week after discontinuation from ECMO support.
Study NCT02836834 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JS001
Description: Dose escalation study evaluating three dose levels (1, 3 and 10 mg/kg) of JS-001.Each of the 3 dose levels will use 2 dose schedules: single dose, and repeated doses every 2 weeks. Subjects will be assigned to a dose schedule in the order of study entry.
Study NCT01453413 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood Glucose meter
Description: Staff tested subject Blood Glucose using a Blood Glucose meter.
Study NCT01189526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Ranibizumab 0.5mg Ranibizumab will be administered to patients as multiple intravitreal injections.
Study NCT01189526 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: macular laser photocoagulation
Description: Treatment may include both focal and grid therapy using the laser and contact lens of the investigator's choice.
Study NCT03898674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intra venous fluid
Description: Volume of intra venous fluid administered during GDT protocol
Study NCT03896464 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Soft tissue hamstring autograft
Description: Patients will be prescribed to receive a soft tissue hamstring autograft to for ACL reconstruction.
Study NCT03896464 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quadriceps tendon autograft
Description: Patients will be prescribed to receive a quadriceps tendon autograft to for ACL reconstruction.
Study NCT00910767 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Conventional insulin pump delivery
Description: Subcutaneous delivery of Novorapid insulin according to usual pump regime
Study NCT00910767 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed loop
Description: Subcutaneous delivery of Novorapid insulin, dose calculated by control algorithm, based on continuous glucose sensor readings
Study NCT04191798 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telerehabilitation using the KinexConnect system for rehabilitation after TKA.
Description: KinexConnect subjects are asked to Perform CPM therapy for 4 weeks. Perform a KCK home exercise program (HEP) for 6 weeks.
Study NCT04191798 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional outpatient PT for rehabilitation after TKA.
Description: Control subjects are asked to undergo standard outpatient physical therapy (PT) with a licensed physical therapist plus supplemental home exercises as directed. Nominally patients are expected to have 3 PT sessions per week for 4 weeks.
Study NCT00949611 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FRAX + Decision Aid
Description: Clinicians will present patient's with their individualized risk of osteoporotic fracture in 10 years, based on the FRAX risk calculator, as well as sharing a decision aid with them, which shows their risk of fracture, risk reduction on medications, as well as the downsides of the medications.
Study NCT00949611 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FRAX estimated fracture risk
Description: The clinician is provided with the patient's estimated risk of fracture as computed by the FRAX
Study NCT01222910 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valacyclovir hydrochloride
Study NCT01222910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valacyclovir hydrochloride
Study NCT02325063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRP-L Injection
Description: Patients will be treated with an injection of leukocyte and platelet rich plasma.
Study NCT01484184 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SPINALON (buspirone + levodopa + cardidopa)
Description: The proposed study is a combination of 1 and 2-arm designs. First, a 2-arm design will be used, the first arm being composed of 3 subjects receiving the lowest dose of the study drug, and the second arm being composed of 1 subject receiving a placebo. This 2-arm design will be repeated consecutively (not simultaneously) with increasing doses of SPINALON, as long as the dose is well tolerated. Six (6) groups are expected to be tested with this 2-arm design.This will be followed by a 2-arm composed of 1 group with 1 subject receiving placebo and 1 larger group (10 subjects) who will receive SPINALON at MTD as identified in the previous 2-arm groups.
Study NCT01484184 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPINALON (buspirone + levodopa + cardidopa)
Description: The proposed study is a combination of 1 and 2-arm designs. First, a 2-arm design will be used, the first arm being composed of 3 subjects receiving the lowest dose of the study drug, and the second arm being composed of 1 subject receiving a placebo. This 2-arm design will be repeated consecutively (not simultaneously) with increasing doses of SPINALON, as long as the dose is well tolerated. Six (6) groups are expected to be tested with this 2-arm design.This will be followed by a 2-arm composed of 1 group with 1 subject receiving placebo and 1 larger group (10 subjects) who will receive SPINALON at MTD as identified in the previous 2-arm groups.
Study NCT04075019 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Raising Healthy Children intervention, including teacher training, child skill development, and parent training
Study NCT02325063 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botox injection
Description: Patients will be treated with an injection of Type A Botulinum toxin.
Study NCT02325063 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticoid injection
Description: Patients will be treated with an injection of Corticoids.
Study NCT03615417 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Flow Nasal Cannula (HFNC)
Description: Preoxygenation trough High Flow Nasal Cannula (HFNC) at 100% FiO2, 50 liters/min and closed mouth.~After Rapid Sequence Induction (RSI), maintenance of apnea with HFNC at 100% FiO2, 70 liters/min and jaw thrust.~At time of peripheral oxygen saturations (SpO2) decreases by 2% or after 10 minutes of apnea, the participant is intubated.
Study NCT03615417 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard anesthesia FaceMask (FM)
Description: Preoxygenation trough standard anesthesia FaceMask (FM) at 100% FiO2, 12 liters/min, CPAP 7 cmH2O.~After Rapid Sequence Induction (RSI), maintenance of apnea without mask. At time of peripheral oxygen saturations (SpO2) decreases by 2% or after 10 minutes of apnea, the participant is intubated.